ArticleProceedings of the National Academy of Sciences of the United States of America2021
A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Preparing Adjuvanted Nanoliposomes for Applications Toward Recombinant Influenza Vaccine Development.Bio-protocol · 2026Article
- Scalable secretory production of influenza A (H1N1) hemagglutinin HA1 in Pichia pastoris through expression and process optimization.Microbial cell factories · 2026Article
- Hemagglutinin-displaying influenza nanovaccines: progress and promise.Nanomedicine (London, England) · 2026Review
- Priming or Boosting Plasmodium falciparum Transmission-Blocking Responses With Recombinant Vaccines or Gametocyte Extract.The Journal of infectious diseases · 2025Article
- Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Femtosecond laser-ablative aqueous synthesis of multi-drug antiviral nanoparticles.Nanomedicine (London, England) · 2025Article
- Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function.Acta pharmaceutica Sinica. B · 2025Review
- 50-Fold Adjuvant and 20-Fold Antigen Vaccine Dose Sparing from Nanoliposome Display of a Stabilized Malarial Protein Antigen.ACS nano · 2025Article
- Drug-phospholipid conjugate nano-assembly for drug delivery.Smart medicine · 2024Review
- Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.iScience · 2024Article
- Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives.Molecules (Basel, Switzerland) · 2024Review
- Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine.Cell reports. Medicine · 2024Article
- Zinc Carnosine Metal-Organic Coordination Polymer as a Potent Broadly Active Influenza Vaccine Platform with In Vitro Shelf-Stability.Molecular pharmaceutics · 2023Article
- Vinyl Sulfone-functionalized Acetalated Dextran Microparticles as a Subunit Broadly Acting Influenza Vaccine.The AAPS journal · 2023Article
- Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses.Frontiers in immunology · 2023Review
- Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG.Frontiers in immunology · 2023Article
- Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.Pharmaceutics · 2022Article
- Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.Journal of virology · 2022Article
- Materials-based vaccines for infectious diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230.NPJ vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 3 countries.
Funding
Abstract
Recombinant influenza virus vaccines based on hemagglutinin (HA) hold the potential to accelerate production timelines and improve efficacy relative to traditional egg-based platforms. Here, we assess a vaccine adjuvant system comprised of immunogenic liposomes that spontaneously convert soluble antigens into a particle format, displayed on the bilayer surface. When trimeric H3 HA was presented on liposomes, antigen delivery to macrophages was improved in vitro, and strong functional antibody responses were induced following intramuscular immunization of mice. Protection was conferred against challenge with a heterologous strain of H3N2 virus, and naive mice were also protected following passive serum transfer. When admixed with the particle-forming liposomes, immunization reduced viral infection severity at vaccine doses as low as 2 ng HA, highlighting dose-sparing potential. In ferrets, immunization induced neutralizing antibodies that reduced the upper respiratory viral load upon challenge with a more modern, heterologous H3N2 viral strain. To demonstrate the flexibility and modular nature of the liposome system, 10 recombinant surface antigens representing distinct influenza virus strains were bound simultaneously to generate a highly multivalent protein particle that with 5 ng individual antigen dosing induced antibodies in mice that specifically recognized the constituent immunogens and conferred protection against heterologous H5N1 influenza virus challenge. Taken together, these results show that stable presentation of recombinant HA on immunogenic liposome surfaces in an arrayed fashion enhances functional immune responses and warrants further attention for the development of broadly protective influenza virus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.